Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,506.48
(
-1.51%
)
US TECH 100
23,484.80
(
-0.99%
)
Dow Jones
45,577.47
(
-0.96%
)
Brent Oil
109.05
(
0.85%
)
Bitcoin
68,049.71
(
0.31%
)
News Focus
News Focus
Post# of 257269
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122806
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: dewophile post# 166972

Wednesday, 09/25/2013 11:52:59 AM

Wednesday, September 25, 2013 11:52:59 AM

Post# of 257269
Good sleuthing on ENTA, although I would temper the enthusiasm for ABT-493 to some degree by nitpicking that “pan-genotypic activity” in preclinical studies is not exactly the same as asserting that the ABT-493 + ABT-530 regimen will be pan-genotypic (which the companies have not yet done).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today